Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Liver Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


6 drugs have received FDA approval for Liver Cancer . Cabozantinib-S-Malate, Lenvatinib Mesylate, Nivolumab, Pembrolizumab, Regorafenib and Sorafenib Tosylate
284 drugs have a clinical trial registered for Liver Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 1757 clinical trials for Liver Cancer,
886 of which have one or more drug interventions,
871 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 82 Cell Line Models for Liver Cancer.

Source: COSMIC
(see details)

Chemistry


There are 7245 Compounds which have been tested in Liver Cancer , 4425 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Liver Cancer:
Carcinoma, Hepatocellular
Hepatoblastoma
Liver Neoplasms
Liver Neoplasms, Experimental

The following terms have been mapped from cancer.gov to Liver Cancer:
Hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery
Hepatocellular carcinoma (a type of liver cancer). It is used as first-line treatment in patients whose disease cannot be removed by surgery
Hepatocellular carcinoma (a type of liver cancer) in patients who have been treated with sorafenib.????
Hepatocellular carcinoma (a type of liver cancer). It is used in patients who have already been treated with sorafenib
Hepatocellular carcinoma (a type of liver cancer). It is used in patients who have already been treated with sorafenib. This use is approved for the Cabometyx brand of cabozantinib-s-malate